- Approval of All Agenda Items With the Required Majority
- Actions of Management Board and Supervisory Board Approved
- New Supervisory Board Member Elected: Dr. Elaine Sullivan
- Contingent Capital for the Issue of Subscription Rights as Part of Share Performance Plan 2015 Created
- Purchase and Use of Treasury Shares in Accordance with § 71 para. 1 No. 8 AktG Authorised
HAMBURG, Germany, June 09, 2015 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting, which took place today, with the required majority.
The Chief Executive Officer of Evotec AG, Dr. Werner Lanthaler, presented the Company’s performance for the year 2014 and provided the shareholders with an update on the topic “New substances – A matter of efficient connections.”
At the Annual General Meeting, the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2014 were approved. Furthermore, following the resignation of Dr. Walter Wenninger as member and Vice Chairman from the Supervisory Board with effect from the close of today’s Annual General Meeting, Dr. Elaine Sullivan was elected by the Annual General Meeting as new member of the Supervisory Board. The term of Dr. Elaine Sullivan ends, like the term of the other Supervisory Board members, with the close of the Annual General Meeting charged with approving the actions of the members of the Supervisory Board in the 2018 fiscal year.
In a subsequent meeting of the Supervisory Board, Bernd Hirsch, Chief Financial Officer of Symrise AG, was elected as Vice Chairman of the Supervisory Board.
Prof. Dr. Wolfgang Plischke, Chairman of the Supervisory Board of Evotec AG, commented: “On behalf of the Evotec Supervisory Board, I’d like to extend our sincere thanks to Dr. Wenninger for his trustful and invaluable support in the dynamic corporate development of Evotec over the last years. Furthermore, I’m delighted to welcome Mr Hirsch as new Vice Chairman and Dr. Elaine Sullivan as new member of the Supervisory Board.”
“I’d like to express my sincere gratitude to Dr. Walter Wenninger, also on behalf of my colleagues in the Management Board, for his constructive and successful collaboration over the last years,” added Dr. Werner Lanthaler, Chief Executive Officer of Evotec. “At the same time, I’d like to warmly welcome Dr. Elaine Sullivan to the Supervisory Board of Evotec AG.”
The Annual General Meeting also approved the proposal of the Management Board and the Supervisory Board to create a new contingent capital for the issue of subscription rights as part of Share Performance Plan 2015 and authorised the purchase and use of treasury shares in accordance with § 71 para. 1 No. 8 AktG. Moreover, the Annual General Meeting passed the other agenda items requiring shareholders’ approval, hereunder the appointment of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, Hamburg, as the auditor for fiscal year 2015 and the resolution to clarify the authorisation to issue subscription rights as part of a Share Performance Plan 2012.
At the ordinary Annual General Meeting 2015 of Evotec AG, 40.31% of the voting capital was present.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease. For additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
For further information, please contact Gabriele Hansen VP, Corporate Communications & Investor Relations +49.(0)40.560 81-255 +49.(0)40.560 81-333 Fax email@example.com Evotec AG Manfred Eigen Campus Essener Bogen 7 22419 Hamburg (Germany)